Author:
Gold Ralf,Radue Ernst-Wilhelm,Giovannoni Gavin,Selmaj Krzysztof,Havrdova Eva,Stefoski Dusan,Sprenger Till,Montalban Xavier,Cohan Stanley,Umans Kimberly,Greenberg Steven J.,Ozen Gulden,Elkins Jacob
Publisher
Springer Science and Business Media LLC
Subject
Clinical Neurology,General Medicine
Reference9 articles.
1. Waldmann TA. The IL-2/IL-2 receptor system: a target for rational immune intervention. Immunol Today. 1993;14:264–70.
2. Wiendl H, Gross CC. Modulation of IL-2Rα with daclizumab for treatment of multiple sclerosis. Nat Rev Neurol. 2013;9:394–404.
3. Gold R, Giovannoni G, Selmaj K, Havrdova E, Montalban X, Radue EW, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet. 2013;381:2167–75.
4. Giovannoni G, Gold R, Selmaj K, Havrdova E, Montalban X, Radue EW, et al. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial. Lancet Neurol. 2014;13:472–81.
5. World Health Organization. Global Tuberculosis Report 2013 [Ukraine country profile]. http://www.who.int/tb/country/data/profiles/en/ . Accessed 12 October 2015.
Cited by
39 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献